Next we assessed the therapeutic potential of combined p53 activation and BCL-xL/BCL-2 inhibition by evaluating the ability of idasanutlin-navitoclax to inhibit growth of patient leukemia cells in vivo. This evidence concerns the gene BCL2 and leukemia.